Actively Recruiting
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-03-13
31
Participants Needed
1
Research Sites
317 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm study to investigate 1-year treatment related mortality (TRM) in patients with life threatening non-malignant and malignant hematologic disorders who do not have a matched related donor for allogeneic transplantation.
CONDITIONS
Official Title
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 21 years or younger at time of consent with no available matched related or unrelated donor
- Diagnosed with AML, ALL, other acute leukemias, MDS or MPD without myelofibrosis, NHL or HL at high risk, inherited metabolic disorders, hemoglobinopathies, bone marrow failure, or HLH
- AML patients must meet specific remission and risk criteria as detailed in the protocol
- ALL patients must meet specific remission and risk criteria as detailed in the protocol
- Other acute leukemias with less than 5% blasts by bone marrow morphology
- MDS/MPD patients with specific risk scores and bone marrow counts as detailed
- NHL or HL patients with specified remission or progression status
- For metabolic diseases, early disease status before neurologic symptoms
- Karnofsky or Lansky score of 70% or higher
- Bilirubin level 1.5 mg/dL or less (unless benign congenital hyperbilirubinemia)
- ALT level 3 times upper limit of normal or less
- Pulmonary function tests at or above 50% predicted
- Left ventricular ejection fraction 50% or higher
- Age-adjusted Hematopoietic Cell Transplantation-Comorbidity Index (aaHCT-CI) of 7 or less
- Renal function with serum creatinine 1.5 times normal or less or adequate creatinine clearance or glomerular filtration rate
- Cord blood graft meeting MSKCC selection criteria with appropriate HLA matching and cell dose
You will not qualify if you...
- Inadequate performance status or organ function
- Advanced metabolic disease
- Active central nervous system leukemic involvement
- Indolent NHL or HL with disease progression after most recent chemotherapy
- Diagnosis of myelofibrosis or malignancy with moderate to severe bone marrow fibrosis
- Autologous stem cell transplant within 6 months before enrollment
- Any prior allogeneic stem cell transplant
- Active and uncontrolled infections at time of transplantation
- HIV infection
- Seropositivity for HTLV-1
- Pregnancy or breastfeeding
- Inability of patient or guardian to provide informed consent or comply with treatment protocol and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Actively Recruiting
Research Team
M
Maria I Cancio, MD
CONTACT
J
Jaap Jan Boelens, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here